| Name | Title | Contact Details |
|---|
Troy Medicare started in Concord, North Carolina with several pharmacists seeing people increasingly unable to afford their prescriptions. Health plans had become more expensive and less transparent in their drug pricing.
NantHealth is a transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system. NantHealth solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical and operational delivery with real time actionable clinical data, and promoting wellness for a healthier, happier world. We are building an integrated, evidence-based, omically-informed, personalized approach to the delivery of care and the development of next generation healthcare solutions. NantHealth is a subsidiary of NantWorks a company founded and led by Dr. Patrick Soon-Shiong. NantWorks is a convergence of next generation machine vision, object and voice recognition technologies, ultra-low power semiconductors, supercomputing, and advanced networks for the purpose of bringing the digital revolution to healthcare, commerce, and digital entertainment to an entirely new level. NantHealth envisions a world in which cutting-edge developments in science, technology, infrastructure and human ingenuity converge to advance one extraordinary mission: transforming healthcare for the benefit of every patient. We merge innovation with infrastructure; empowering more efficient and effective clinical decisions through advanced and actionable health information. By improving the accuracy and timeliness of data, we can deliver targeted healthcare intelligence for evolutionary personalized care. Our ultimate mission is to empower progress through uniquely informed decisions; to bring the impossible to life by harnessing the power of convergence for the well-being of humanity.
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
Haemoscope Corporation is a Niles, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.